%PDF-1.4
%
69 0 obj
<>
endobj
66 0 obj
<>
endobj
131 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-11T16:17:41Z
2024-03-28T16:07:51-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:07:51-07:00
application/pdf
Heather
2002-805.june
uuid:ef7a125a-1dd1-11b2-0a00-0a0927bd3700
uuid:ef7a125e-1dd1-11b2-0a00-5b0000000000
endstream
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
19 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
22 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
165 0 obj
[169 0 R]
endobj
166 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(scores: evidence for the role of low back pain, symptom counts,)Tj
0 -1.25 TD
(fatigue and depression in osteoarthritis, rheumatoid arthritis and)Tj
T*
(fibromyalgia. Rheumatology Oxford 1999;38:355-61.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.9 (.)]TJ
2.175 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
T*
(measuring clinically important patient relevant outcomes to)Tj
T*
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Hurst NP)110.7 (, Kind P)110.7 (, Ruta D, Hunter M, Stubbings )54.8 (A. Measuring)]TJ
2.175 -1.25 Td
[(health-related quality of life in rheumatoid arthritis: )17.7 (V)110.8 (alidity)64.8 (,)]TJ
T*
(responsiveness and reliability of EuroQol \(EQ-5D\). Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:551-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. Measurement of the quality of life in)]TJ
2.175 -1.25 Td
(rheumatic disorders using the EuroQol. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:786-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Stata Corporation. Stata statistical software: Release 7.0. College)]TJ
2.175 -1.25 Td
[(Station, )17.7 (TX: Stata Corp.; 2001.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (W)79.9 (olfe F)79.7 (, Flowers N, Burke )17.7 (T)79.9 (A, )54.8 (Ar)17.7 (guelles LM, Pettitt D. Increase in)]TJ
2.175 -1.25 Td
(lifetime adverse drug reactions, service utilization, and disease)Tj
T*
(severity among patients who will start COX-2 specific inhibitors:)Tj
33 23.75 Td
(quantitative assessment of channeling bias and confounding by)Tj
T*
(indication in 6689 patients with rheumatoid arthritis and)Tj
T*
(osteoarthritis. J Rheumatol 2002;29:1015-22.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Bombardier C, Laine L, Reicin )54.8 (A, et al. Comparison of upper)]TJ
2.175 -1.25 Td
(gastrointestinal toxicity of rofecoxib and naproxen in patients with)Tj
T*
[(rheumatoid arthritis. )17.7 (VIGOR Study Group. N Engl J Med)]TJ
0 Tc 0 Tw T*
(2000;343:1520-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (T)69.9 (annenbaum H, Davis P)110.7 (, Russell )54.8 (AS, et al. )54.8 (An evidence-based)]TJ
2.175 -1.25 Td
(approach to prescribing NSAIDs in musculoskeletal disease: a)Tj
T*
(Canadian consensus. Canadian NSAID Consensus Participants.)Tj
0 Tc T*
(CMAJ 1996;155:77-88.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the)]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy of antihypertensive drugs. )54.8 (A)-220.1 (randomized, double-blind,)]TJ
T*
(placebo-controlled trial of ibuprofen compared with )Tj
T*
[(acetaminophen. )54.8 (Ann Intern Med 1987;107:628-35.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(W)91.9 (olfe, et al: NSAID use and hypertension)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1151)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
120.98 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>stream
8;Z\u=Ur=l$q0:X(\DjMer8u#65G]E,B5rFnPH-GGNtRHR&Q4"[RtE$JOf(s9
S)BO2eV/$.BN/]p/7KD*bQ>NOaX0SGF#%[Jh-k`6"&XT:"7(OGmt4O<]4!Ac3nS4[
Y,H0bdsG3&):GjJBa=&mSUA@[Jp(fOZI*SU)2EWJ3I:k3Y(pSq+/VFan>]K,`
;-X\nS2LC_2!`icCg!B\VobUemjR.qFtOaBA&$0QLS'HncFG9M6g8)(KFgHU+bUCn
#dF_AB8O]\ij.AX(Vo3`C%
endstream
endobj
53 0 obj
[/Indexed/DeviceRGB 255 52 0 R]
endobj
52 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
112 0 obj
<>
endobj
76 0 obj
<>
endobj
72 0 obj
<>
endobj
93 0 obj
<>
endobj
136 0 obj
<>
endobj
73 0 obj
<>
endobj
85 0 obj
<>stream
HUiPSYcl D5"2V ",4DBXBBd B 1`vM#Z3=TLM:U_:瞯ww1 0݁ׄyu$w4Ab2
GF[/YVhJI֊Z%0e0킗.A8 >kΆ~]}fΎ8A,sX,TAzpv$%q
9